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A B S T R A C T
Background
Malaria is transmitted through the bite of Plasmodium-infected adult female Anopheles mosquitoes. Ivermectin, an anti-parasitic drug,
acts by killing mosquitoes that are exposed to the drug while feeding on the blood of people (known as blood feeds) who have ingested
the drug. This eGect on mosquitoes has been demonstrated by individual randomized trials. This eGect has generated interest in using
ivermectin as a tool for malaria control.
Objectives
To assess the eGect of community administration of ivermectin on malaria transmission.
Search methods
We searched the Cochrane Infectious Diseases Group (CIDG) Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, Science Citation
index - expanded, the World Health Organization (WHO) International Clinical Trials Registry Platform, ClinicalTrials.gov, and the National
Institutes of Health (NIH) RePORTER database to 14 January 2021.
We checked the reference lists of included studies for other potentially relevant studies, and contacted researchers working in the field for
unpublished and ongoing trials.
Selection criteria
We included cluster-randomized controlled trials (cRCTs) that compared ivermectin, as single or multiple doses, with a control treatment
or placebo given to populations living in malaria-endemic areas, in the context of mass drug administration. Primary outcomes were
prevalence of malaria parasite infection and incidence of clinical malaria in the community.
Data collection and analysis
Two review authors independently extracted data on the number of events and the number of participants in each trial arm at the time
of assessment. For rate data, we noted the total time at risk in each trial arm. To assess risk of bias, we used Cochrane's RoB 2 tool for
cRCTs. We documented the method of data analysis, any adjustments for clustering or other covariates, and recorded the estimate of the
intra-cluster correlation (ICC) coeGicient.
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We re-analysed the trial data provided by the trial authors to adjust for cluster eGects. We used a Poisson mixed-eGect model with small
sample size correction, and a cluster-level analysis using the linear weighted model to adequately adjust for clustering.
Main results
We included one cRCT and identified six ongoing trials.
The included cRCT examined the incidence of malaria in eight villages in Burkina Faso, randomized to two arms. Both trial arms received
a single dose of ivermectin 150 µg/kg to 200 µg/kg, together with a dose of albendazole. The villages in the intervention arm received an
additional five doses of ivermectin, once every three weeks. Children were enrolled into an active cohort, in which they were repeatedly
screened for malaria infection.
The primary outcome was the cumulative incidence of uncomplicated malaria in a cohort of children aged five years and younger, over
the 18-week study. We judged the study to be at high risk of bias, as the analysis did not account for clustering or correlation between
participants in the same village.
The study did not demonstrate an eGect of Ivermectin on the cumulative incidence of uncomplicated malaria in the cohort of children over
the 18-week study (risk ratio 0.86, 95% confidence interval (CI) 0.62 to 1.17; P = 0.2607; very low-certainty evidence).
Authors' conclusions
We are uncertain whether community administration of ivermectin has an eGect on malaria transmission, based on one trial published
to date.
P L A I N   L A N G U A G E   S U M M A R Y
Malaria control using ivermectin
What is the aim of this review?
The aim of this Cochrane Review was to find out if giving the drug ivermectin to entire communities could reduce malaria transmission.
We examined all relevant studies to answer this question, and found one relevant study.
Key messages
It is not possible to say at this point if treating an entire community with  ivermectin reduces malaria. Several research studies are in
progress; we anticipate they will provide more answers in the future.
What was studied in the review?
Malaria is a disease transmitted to humans through the bite of mosquitoes infected with Plasmodium parasites. It results in nearly half
a million deaths every year. Ivermectin is a drug that is given to whole communities to control the parasites that are responsible for
elephantiasis and river blindness. It has been observed that ivermectin can kill mosquitoes when they feed on the blood of people who
have taken this medication. Therefore, it is believed that by giving this drug to whole communities, it will kill many mosquitoes, and could
reduce malaria transmission.
In this review, we assessed whether treating entire communities with ivermectin would reduce malaria transmission. We looked for studies
from diGerent sources, and only included studies that took place in communities with malaria, and that randomly assigned groups of
people to ivermectin or a control, which could be a placebo or standard community drug treatments. We wanted to know if the treatment
influenced the occurrence of malaria in the community.
What are the main results of the review?
One study met the inclusion criteria. This study included eight villages in Burkina Faso, which were randomly assigned to receive ivermectin
or a control. All villages received ivermectin, as part of the scheduled control of lymphatic filariasis. In addition, the treatment villages
received five more doses of ivermectin, once every three weeks. The eGect of ivermectin on malaria was measured in children younger than
five years of age. In these children, the treatment did not show a notable diGerence in the presence of malaria between the treatment and
control groups (very low-certainty evidence).
Therefore, it is not possible to say at this point if the treatment of entire communities with ivermectin has an eGect on reducing malaria.
Several studies are currently ongoing; we anticipate they will provide more answers in the future.
How up-to-date is this review?
We searched for studies published up to 14 January 2021.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Ivermectin versus control in humans to reduce malaria transmission
Ivermectin treatment in humans for reducing malaria transmission
Patient or population: adults and children living in malaria-endemic areas
Setting:  villages in Burkina Faso
Intervention: single dose ivermectin 150 μg/kg to 200 μg/kg + 400 mg albendazole + 5 additional doses of ivermectin








































2460 per 1000 344 fewer per 1000 (from




590 (1 cRCT) ⊕⊝⊝⊝
Very lowa,b,c






19 per 1000 12 more per 1000 (0 fewer to
32 more)
RR 1.63 (1.00 to
2.67)
2712 (1 cRCT) ⊕⊝⊝⊝
Very lowd,e
 
We are uncertain whether or not repeat
mass ivermectin administration results in
more adverse events.
CI: confidence interval; MDA: mass drug administration; cRCT: cluster-randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true eGect lies close to that of the estimate of the eGect.
Moderate certainty: we are moderately confident in the eGect estimate: the true eGect is likely to be close to the estimate of the eGect, but there is a possibility that it is
substantially diGerent.
Low certainty: our confidence in the eGect estimate is limited: the true eGect may be substantially diGerent from the estimate of the eGect.
Very low certainty: we have very little confidence in the eGect estimate: the true eGect is likely to be substantially diGerent from the estimate of eGect.
aDowngraded by two levels for risk of bias: due to bias arising from the timing of identification and recruitment of individual participants, and bias in the selection of the reported
result.







































































































































































cDowngraded by one level for indirectness: outcome was uncomplicated malaria, measured in children only.
dDowngraded by two levels for risk of bias: bias arising from the timing of identification and recruitment of individual participants, and bias in the selection of the reported result.
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B A C K G R O U N D
Malaria is an important vector-borne disease, with an estimated
229 million cases and 409,000 deaths annually (WHO 2020). It is
caused by infection with the Plasmodium parasite.  Plasmodium
falciparum and Plasmodium vivax are the main Plasmodium species
that cause persistent blood-stage infections in humans, which
last  several weeks and months (Ashley 2014). In sub-Saharan
Africa, the main mosquito species responsible for transmission are
Anopheles gambiae sensu stricto, An  funestus, and An  arabiensis.
An  gambiae sensu stricto is considered the most eGicient of the
malaria vectors, and preferentially feeds on humans (Hay 2004).
Preventing mosquito bites is key to controlling malaria infection,
and the use of long-lasting insecticide-treated bed nets (LLINs) and
indoor residual spraying (IRS) with insecticides are central to this
strategy (Killeen 2014; Russell 2013). About 57% of people living
in sub-Saharan Africa now have access to a treated bed net (WHO
2019a). Compared to estimates  at the beginning of the century,
the global incidence of malaria cases and deaths has significantly
declined, with a 44% reduction in deaths in the World Health
Organization (WHO) African region (WHO 2020). It is estimated
that vector control interventions contributed to averting over 600
million clinical cases between 2000 and 2015 (Bhatt 2015).
Although progress in malaria control has slowed, the significant
reduction in disease burden has prompted optimism for progress
towards elimination in areas where reductions have been
substantial, and  for accelerating control measures to prevent a
resurgence in transmission   (WHO 2020). The large scale use of
drugs and insecticides for elimination also raises concerns about
increasing resistance to interventions considered the mainstay of
control strategies. Insecticide resistance can manifest as changing
vector behaviour in response to insecticide exposure, such as
insecticide avoidance, outdoor biting preferences, and early exit
behaviour  by indoor-feeding vectors (Killeen 2014; Sougoufara
2014; Thomsen 2017). These vector behaviour changes reduce the
eGectiveness of vector control interventions.
Additional interventions and strategies are clearly needed  to
sustain the gains made  (Feachem 2019; WHO 2019b), and contain
the spread of resistant vectors and parasites (Churcher 2016;
Riveron 2016).
Given that a competent vector needs to live long enough to allow
parasite development in the vector and subsequent transmission
to a human host, reducing the survival and fitness of mosquitoes is
important for the control of malaria transmission. The incubation
period of P falciparum in the mosquito is between 12 and 18 days,
at temperatures of about 24 °C (Blanford 2013). Furthermore, the
reproductive cycle   of the mosquito, from blood feeding, blood
meal digestion, egg maturation, to laying eggs, is shorter than the
period of parasite development in the mosquito (Clements 1992). In
An gambiae mosquitoes, the reproductive cycles could be as short
as two days (Quiñones 1997). Thus, female mosquitoes that live
long enough to transmit parasites are more likely to have achieved
reproductive success (Sy 2014).
Therefore, increasing the mortality rate of infected mosquitoes
could significantly reduce the risk of transmission. One such
method is the use of systemic insecticides or endectocides (used for
the control of both endoparasites and ectoparasites). Ivermectin,
a microfilaricide used for the control of veterinary and human
helminths, but toxic to mosquitoes, has shown great potential
(Derua 2015).
Description of the condition
Malaria transmission involves stages of growth and development
in both humans and the mosquito vector. Strategies to control
transmission are either preventive or therapeutic, and target
parasite stages in humans or the mosquito vector (Graves 2018;
Sinclair 2009).
Interventions against  the mosquito vector rely on the biting and
resting behaviours of mosquitoes (Paaijmans 2011). For example,
insecticides on LLINs and IRS are designed for contact with the
mosquito while indoors. They do not aGect the parasite directly,
but shorten the lifespan of the mosquito vector, thus, they interrupt
the progression of the parasite cycle.
Interventions intended to have an impact on malaria transmission
must be delivered on a large scale, for eGect. These mass drug
treatment campaigns have been implemented in the past as
part of malaria elimination programmes (Nájera 2011). Mass drug
administration (MDA) involves treating entire populations in a
geographical area with a therapeutic dose of a drug, regardless
of the presence of symptoms, and without the need to determine
infection status. Following reductions in the global malaria burden,
there has been renewed interest in MDA to reduce malaria
transmission (Newby 2015; Poirot 2013).
Description of the intervention
Ivermectin is a broad-spectrum, anti-parasitic drug, used
extensively for the treatment of a number of parasites in animals
and humans (Burg 1979). In humans, it is mainly used in the
treatment of onchocerciasis and lymphatic filariasis (Brown 2000;
Cupp 2011), and is delivered through mass treatment campaigns
(Makunde 2003; Molyneux 2003).
Ivermectin binds selectively and strongly to glutamate-gated,
chloride ion channels in muscles and nerve cells of invertebrates
(Meyers 2015), and increases the permeability of their cell
membrane to chloride ions. This process disrupts gamma-
aminobutyric acid (GABA)-mediated neurosynaptic transmission
in the central nervous system, resulting in flaccid paralysis and
death (Ikeda 2003). While humans lack the specific glutamate-
gated channels that bind ivermectin, GABA-gated channels are
expressed that might cross-react with ivermectin (Wolstenholme
2012). Nonetheless, ivermectin is generally considered safe in
humans, but toxic to organisms, such as mosquitoes.
Ivermectin is readily absorbed in humans following ingestion
(Edwards 1988), and reaches peak plasma concentrations within
four hours (Elkassaby 1991). However, it is quickly metabolized,
with a half-life of about 18 hours (Merck 2009). Ivermectin is widely
distributed in the body, mostly in fatty tissue (González Canga
2008), and high concentrations have been observed in individuals
with raised body mass index (Ouédraogo 2015).
Ivermectin is not recommended in areas co-endemic for Loa
loa, as serious adverse reactions, including encephalopathy,
extrapyramidal neurological signs, and  in extreme cases, death,
have been associated with its use (Boussinesq 2001; Gardon 1997).
Ivermectin is also not recommended for use by pregnant women
(Nicholas 2020), and children younger than five years (Farrar 2013).
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Ivermectin, the prototype endectocide, could have a role in mass
treatment towards malaria elimination (Chaccour 2010; Derua
2015). In order to accelerate the re-purposing of ivermectin
for malaria control and elimination, the WHO Global Malaria
Programme published the preferred product characteristics for the
use of endectocides as alternative interventions for controlling
malaria transmission (WHO 2017a). A WHO technical consultation
meeting recommended a 20% target reduction in malaria incidence
for one month aVer MDA with a single round of ivermectin alone,
or a significant reduction in malaria incidence for up to 12 months
post-intervention, if used in combination with artemisinin-based
combination therapy (ACT), and core vector control interventions
for malaria control, as benchmarks for impact (WHO 2017b).
How the intervention might work
Background
Ivermectin may reduce malaria transmission by shortening  the
lifespan of Anopheles mosquitoes exposed to the drug. For impact,
the endectocidal eGect  must be sustained long enough to limit
vector capacity.  This can be achieved by giving higher doses,
multiple doses, or using slow-release preparations. However, the
eGicacy must be balanced  against the risk of side eGects, which
may increase at higher doses (Chaccour 2017). Modelling studies
have predicted that ivermectin could have a significant eGect
when used alone, or as a complementary intervention, in high
transmission settings, in areas suitable for elimination, and may
be most eGective in areas with short transmission seasons (Slater
2020). However, these models are based on data using laboratory-
reared mosquitoes, which may behave diGerently compared to wild
mosquitoes (Slater 2020).
The endectocidal eGect of ivermectin  has been studied mainly
by in vitro experiments, where lab-reared mosquitos feed on
ivermectin preparations via a membrane, and by  in vivo studies,
where mosquitos are allowed to feed on individuals' blood aVer
they have taken oral ivermectin (Alout 2014; Chaccour 2015; Derua
2015; Foley 2000; Kobylinski 2011). These studies demonstrate that
the eGect on mosquito mortality depends on the concentration of
the drug in the blood, and the length of time drug concentrations
remain above the lethal threshold. Sublethal eGects of ivermectin
have also been described, and include delayed re-feed time,
inhibiting the development of sporozoites, and reductions in
fertility and egg hatch rates (Chaccour 2017).  Endectocidal and sub-
lethal outcomes in these studies have been reported in diGerent
formats, which creates a challenge for interpreting the eGect.
Systematic review of randomized controlled trials
of ivermectin on mosquito mortality
The main Cochrane Review assesses the ability of  ivermectin to
reduce malaria transmission in the community.
However, to assess the evidence behind the theory that ivermectin
may have an eGect on transmission, we briefly present our
systematic review of the evidence that ivermectin has an eGect on
mosquito mortality. The full details of this  systematic review are
in Appendix 1.
Our inclusion criteria were randomized controlled trials
(RCTs),  conducted in healthy or malaria-infected people, who
were given oral ivermectin, and then either gave  blood for
membrane feeding,  or  allowed Anopheles species mosquitoes to
feed directly on their arms. Studies measured cumulative mortality
in the mosquitoes that were given access to the blood through
membrane or direct feeding. We searched the Cochrane Central
Register of Controlled Trials (CENTRAL; 14 January 2021, Issue
1 of 12) in the Cochrane Library (searched 14 January 2021),
MEDLINE Pubmed  (1946 to 14 January 2021), Embase Ovid,
(1974 to 14 January 2021), and Web of Science (searched 14
January 2021), using the search terms: ivermectin or avermectin
OR abamectin) AND Anopheles or mosquitocid*.   Two review
authors (RT and JO) applied the inclusion criteria, and resolved any
discrepancies by discussion. We used tabular data to summarise
the outcome measures, as time points and mortality measures are
highly variable.
We identified 198 articles, five of which we included (Chaccour
2010; Derua 2015; Mekuriaw 2019; Ouédraogo 2015; Smit 2018).
In these studies, participants received oral ivermectin, aVer
which,  feeding experiments, using laboratory-reared mosquitoes
were conducted at set time points. The data showed that
ivermectin has a large eGect on mosquito mortality. This eGect was
associated with the dose of ivermectin, and the time between the
ingestion of ivermectin and the feeding experiment. The eGect also
appeared  to diGer with mosquito species. A full summary of the
results are presented in Appendix 1.
These findings are consistent with results from non-randomized
studies and ivermectin-based MDAs against other mosquito-borne
diseases, such as lymphatic filariasis and onchocerciasis (Alout
2014; Kobylinski 2011; Kositz 2017; Sylla 2010; Tesh 1990).
Why it is important to do this review
There  is a need for consensus in determining and defining
outcome measures, methods for data analysis, and interpretation
of results, to support decisions on the role of ivermectin in reducing
malaria transmission in endemic populations.
Our systematic review of five published studies showed a
consistent and dose-dependent eGect of oral ivermectin treatment
in humans on mosquito mortality (Appendix 1). The studies also
found that the observed mosquito mortality decreased  as the
time  following ivermectin ingestion increased. Higher doses of
ivermectin prolonged this eGect, indicating a longer time of lethal
concentration of ivermectin in the participants' blood.
However, it is unclear whether  this translates to reduced
malaria transmission in endemic populations with wild mosquito
vectors.  In addition, the association between entomological
endpoints, such as mosquito mortality and epidemiological
indicators of impact, have not been validated. Other factors, such
as bed net and insecticide usage, may aGect the eGectiveness of the
intervention.
Presently, there is one published trial on the eGect of oral
ivermectin on malaria transmission (Foy 2019), and a number of
Ongoing studies, with results expected in forthcoming years. This
Cochrane Review provides a critique of the existing study, and
highlights considerations for data analysis  and presentation of
results from subsequent trials, which will support a comprehensive
update of this review.
Ivermectin treatment in humans for reducing malaria transmission (Review)
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O B J E C T I V E S
To assess the eGects of community administration of ivermectin on
malaria transmission.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included cluster-randomized controlled trials (cRCTs) that
compared mass administration of ivermectin to either infected or
uninfected people versus control or standard mass drug regimes
given to the whole population. Studies in which  ivermectin was
administered to animals were considered if there was simultaneous
administration to the human population.
Because the interventions considered in this review are at the
community level, and the primary outcomes are population-based
malaria transmission indices,  cRCTs are the most appropriate
design to estimate unbiased causal eGects at the level of
communities, which are relevant for policymakers.
Types of participants
We included adults and children living in malaria-endemic areas.
Types of interventions
Intervention
Community mass drug administration (MDA) of ivermectin, given
alone or together with other treatments, as single or multiple
doses.
Control
Placebo or no treatment.
Other drugs administered as part of the usual MDA programme in
the study area, as long as they were given to both intervention and
control arms. Ivermectin was considered an appropriate control if
this was part of the existing drug administration programme in the
study area, and diGered in dose from the intervention arm.
Types of outcome measures
The primary outcome measures were amended prior to the
screening process to prioritize population-based outcomes
important for health policy.
Primary outcomes
• Prevalence of malaria parasite infection measured by
microscopy, rapid diagnostic tests (RDTs), or molecular methods
• Incidence of clinical malaria, defined by symptoms with
parasitaemia, detected by microscopy or RDTs
Secondary outcomes
• Mosquito mortality or survival at one, three, and nine days post-
treatment
• Mosquito density (number of each mosquito species in the study
area, determined by trapping experiments)
• P falciparum sporozoite rates (the proportion of female
anopheline mosquitoes with P falciparum sporozoites in their
salivary glands)
• P falciparum oocyst rates (the proportion of female anopheline
mosquitoes with P falciparum oocysts in their gut)
Adverse e:ects
• Serious adverse eGects (deaths, disability, hospitalization)
• Other adverse events, which may be local or systemic, but do not
meet a classification as serious)
Search methods for identification of studies
We searched for all relevant studies regardless of date, language, or
publication status.
Electronic searches
The Cochrane Infectious Diseases Group (CIDG) Information
Specialist searched the following databases, using the search
terms detailed in Appendix 2:   the CIDG Specialized Register;
the Cochrane Central Register of Controlled Trials (CENTRAL,
2021, Issue 1), in the Cochrane Library (searched 14
January 2021); MEDLINE PubMed  (1966 to 14 January 2021);
Embase OVID  (1947 to 14 January 2021); Latin American
Caribbean Health Sciences Literature (LILACS  BIREME;  1982
to 14 January 2021); and Science Citation index - Expanded
Web of Science (1900 to 14 January 2021), We also
searched the World Health Organization (WHO) International
Clinical Trials Registry Platform (www.who.int/ictrp/search/en/);
ClinicalTrials.gov (clinicaltrials.gov/);  and the National Institutes
of Health (NIH) RePORTER database (projectreporter.nih.gov/
reporter.cfm), using (ivermectin OR avermectin OR abamectin) and
(malaria OR mosquit*).
Searching other resources
We checked the reference lists of the included study  for other
potentially relevant studies. We contacted researchers working in
the field to ask about unpublished and ongoing trials.
We searched the MESA Track: a living database of research
projects focusing on malaria eradication, to find unregistered trials
in progress (www.malariaeradication.org/mesa-track; searched 8
February 2021).
Data collection and analysis
Selection of studies
Two review authors (DKD and JO) independently screened the
titles and abstracts of the search results for potentially relevant
studies, using predefined eligibility criteria. We reviewed the full-
text of reports identified through this screening, and resolved
disagreements on eligibility by discussion. We considered duplicate
publications from the same study as a single entry. We listed all
studies excluded aVer full-text assessment in a Characteristics of
excluded studies table. The selection process is presented in a
PRISMA diagram (Figure 1).
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Figure 1.    PRISMA flow diagram detailing the database search results and study selection process
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Data extraction and management
Two review authors (DKD and  RT) independently extracted data
using a pre-tested extraction form, with diGerences in extracted
data resolved in discussion with a third review contributor (Dr
Birhanu Ayele). In order to evaluate causes of heterogeneity, we
extracted data on study design; study population and setting
(country); frequency of ivermectin administration; duration of
follow-up for both human and mosquito populations; and methods
for ensuring comparability between sites in multisite studies. We
also extracted estimates of outcomes of interest, together with their
corresponding measures of precision for our meta-analysis.
For dichotomous variables, we extracted data on the number of
events and the number of participants in each trial arm at the time
of assessment. For rate data, we extracted the number of events in
the treatment and comparison group, and the total time at risk in
each trial arm. For cRCTs, we recorded the unit of randomization,
the number of clusters, and the average size of each cluster.
We documented details about adjustment for clustering or other
covariates, such as the intra-cluster correlation (ICC) coeGicient. We
contacted the study authors for additional information when this
was unclear in the trial report.
Assessment of risk of bias in included studies
Four review authors (CL, RT, DKD, and JO) independently assessed
the risk of bias of the  included studies,  using Cochrane's RoB
2  for cRCTs (Eldridge 2021). When  there were diGerences in
judgments, we came to a  group consensus, including review
authors  RT, JO, and DKD. We used the ROB 2 tool  for cRCTs
MicrosoV Word template, November 2020 version, to complete the
assessment (Sterne 2019). We assessed the risk of bias for intention-
to-treat eGects for the primary outcomes, malaria incidence and
adverse events. We assessed items under the following domains:
• Risk of bias in the randomization process
• Bias in the timing of identification and recruitment of individual
participants in relation to the timing of randomization
• Bias due to deviations from the intended interventions
• Bias due to missing outcome data
• Bias in the measurement of the outcome
• Bias in the selection of the reported result
We reported the judgements as 'low', 'some concerns', or 'high'. We
generated a summary risk of bias table based on our observations
using the Risk-of-bias VISualization (robviz) tool (McGuinness 2020).
The recorded consensus decisions are stored as supplemental
data. We judged studies to have a high risk of bias when we judged
one domain to be at high  risk of bias, or where we found some
concerns  in multiple domains, unless we could  justify a diGerent
judgment.
Measures of treatment e:ect
We compared the incidence of clinical malaria episodes by
calculating the risk  ratio and the mean diGerence in rates of
episodes between treatment arms. We presented eGect estimates
with 95% confidence intervals (CIs).
We compared the frequency of adverse events between treatment
arms as absolute numbers, risk ratios, and risk diGerences with 95%
CIs.
Unit of analysis issues
The search focused on cRCTs only, so we sought to account for
clustering (at the level used for randomization) in the analysis, in
order to obtain valid CIs and P values. For trials with a small number
of clusters, we applied specific small sample corrections to avoid
an inflation of the type I error rate, that is, a too high probability of
showing a statistically significant intervention eGect when there is
none (Kahan 2016; Leyrat 2017).
In the included trial, these considerations were ignored, hence, we
re-analysed the data using a Poisson mixed-eGects model with
a small-sample correction to compare rates of malaria episodes
between clusters (units of randomization (Kenward 1997)).
For repeated treatment given to the same participant, we analysed
outcomes as count outcomes. We did  not include the same
participant's data in a  meta-analysis more than once, to avoid
double-counting. To account for variations in treatment eGect
between individual studies, we considered using a random-eGects
model for any planned meta-analysis.
Dealing with missing data
We searched for discrepancies in the published data on participant
numbers and percentage loss for each treatment group. When all
randomized participants were accounted for, we conducted an
intention-to-treat analysis.
Assessment of heterogeneity
We assessed the baseline characteristics of included studies to
determine the suitability of pooling the results in a meta-analysis.
We planned to regard heterogeneity as moderate if the I2 statistic
lay between 30% and 60%; substantial if it was between 59%
and 90%; and considerable if it was between 75% and 100%
(Deeks 2017). We would regard a Chi2 test statistic with a P ≤ 0.10 to
be indicative of statistically significant heterogeneity. We planned
an exploration of clinical and methodological heterogeneity
through consideration of the trial populations, methods, and
interventions, and by visualization of trial results. When we
found  heterogeneity that was at least moderate, we planned a
subgroup analysis to help identify any eGect modification observed
in the result.
Assessment of reporting biases
We could not assess reporting bias since we only included one
trial in the review. We assessed selective outcome reporting in the
included trial as part of the risk of bias assessment.
Data synthesis
We only included one study in the review, but were able to obtain
the primary data from the trial authors, which we re-analyzed.
When  additional trial results become available, we will  combine
study data in  a meta-analysis, if feasible. When appropriate, we
will combine studies with a fixed-eGect meta-analysis model, based
on the generic inverse-variance approach. However, we will use a
random-eGects model in the event of considerable heterogeneity
(I2   statistic over 75%).  We will present results for unadjusted
cRCTs separately if we do not have enough information to adjust
them  for clustering. For outcomes of repeated dosing, we will
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stratify the analysis by the number of rounds of treatment. The
primary analysis will pool data regardless of risk of bias.
Subgroup analysis and investigation of heterogeneity
We did not conduct a  subgroup analysis. In future revisions,
we will  evaluate heterogeneity in results by subgroup analysis
based on malaria transmission intensity (i.e. low- or high-density
infection areas), population treated and assessed for malaria (i.e.
children versus adults), and  ivermectin dose and frequency of
administration (single or multiple doses versus annual or biannual
administration).
Sensitivity analysis
For each study, we analyzed the primary outcome using a Poisson
regression model with a random eGect, to account for clustering
at the level of the unit of randomization, with the Kenward-
Roger correction for small samples (Kenward 1997). To assess the
robustness of the results to diGerent modelling assumptions, we re-
analysed the trial data using:
• a cluster-level analysis of the diGerence in rates of malaria
episodes using a weighted t-test, with weights accounting for the
variability in cluster size. This approach is very robust when only
a few clusters are randomized.
• a random-eGect Poisson regression without a small sample
correction, to check the impact on power of the small sample
correction
• generalized estimating equations (GEEs) with an exchangeable
correlation structure, with and without a small sample
correction, to estimate population-average, rather than cluster-
specific eGects (Huang 2016).
When additional trial results become available, we will conduct a
sensitivity analysis to assess the eGects of restricting the analysis
to trials with low  or low plus  some concerns in the risk of bias
assessment.
Summary of findings and assessment of the certainty of the
evidence
We assessed the certainty of the evidence using the GRADE
approach (Schünemann 2013). We appraised the certainty of the
evidence in relation to the following criteria: study design, risk of
bias, inconsistency, indirectness, imprecision, other considerations
(including publication bias).
We generated a summary of findings  table for our primary
outcomes when data was available and adverse events, using
GRADEpro GDT (GRADEpro GDT).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
We identified 119 records through our searches. We removed
duplicates, leaving 112 records and we screened all articles for
possible inclusion. AVer title and abstract screening, we excluded
91 ineligible trials.  We assessed 21 full-text articles for eligibility
and excluded 14 articles for the following reasons: two trials did
not have the required outcomes, four had the wrong study design,
and eight were not cluster-randomized. One trial met the inclusion
criteria with six identified ongoing trials (Figure 1).
Included studies
One study met the inclusion criteria (Foy 2019). This was
a cluster-randomized pilot study conducted in Burkina Faso,
a malaria-endemic country with highly seasonal transmission
(Ouédraogo 2013). Study villages were the unit of randomization,
and a total of eight villages were included in the study; four villages
per arm. This trial was registered as a pilot study, and powered as
such.
Participants in both trial arms received a single dose of ivermectin
150 µg/kg to 200 µg/kg,  together with a dose of albendazole,
as part of the scheduled control of lymphatic filariasis. Villages
in the intervention arm received an additional five doses of
ivermectin, one every  three weeks  (Foy 2019). The primary
outcome, cumulative malaria incidence, was measured in a cohort
of children, aged five years and younger. Malaria prevalence was not
measured in this trial.
In total, 563 (20.7%) of the study village population were excluded
from MDA for various reasons; height less than the required 90 cm,
pregnant women, nursing mothers within the first week of birth,
and people with a history of travel to a Loa loa endemic area. Of
the children in the primary outcome monitoring cohort, 21% (121
of 590) met the criteria to receive ivermectin.
The primary outcome was the cumulative incidence of
uncomplicated malaria, measured in the cohort of 590  children
(263 children in the control villages and 327 children in the
intervention villages) over an 18-week intervention period. An
uncomplicated malaria episode was defined as a child with a
temperature of at least 38.0°C, or a history of fever in the preceding
24 hours, and  a positive malaria rapid diagnostic test. Other
measured outcomes  were: the passive case detection of  the
number and type of adverse events following ivermectin ingestion,
and serological reactivity to anopheline salivary gland protein.
Entomological outcomes included human biting rate, sporozoite
rate, entomological inoculation rate, and mosquito parity.
We contacted the study authors for the use of the primary data for
re-analysis. The lead author kindly supplied and approved the use
of the primary data.
Excluded studies
We excluded 14 studies, and listed the reasons in the Characteristics
of excluded studies.
Ongoing studies
We identified six ongoing studies in the trials registers
(Rabinovich ongoing; NCT04844905 (MATAMAL); NCT03074435
(REACT); NCT03576313 (MASSIV); NCT03967054 (RIMDAMAL II);
PR150881). See details in Characteristics of ongoing studies.
Risk of bias in included studies
Please see Figure 2 for the risk of bias summary. A supplementary
file containing details of the RoB 2 consensus judgments is available
on request from the CIDG editorial base.
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Figure 2.   Summary of risk of bias for each outcomes, across domains
 
For the primary outcome of malaria incidence, we judged the study
to have an overall high risk of bias, due to the high risk of bias in
the identification or recruitment of participants in the cRCT, and
in the selection of the reported result. The enrolment of individual
participants took place aVer randomization, and we  judged that
knowledge of the decision could have influenced participation.
Baseline imbalances in bed net use could represent diGerential
recruitment, however, with a few clusters, the imbalances could be
due to chance (Table 1). We judged there to be a high risk of bias
due to multiple eligible measurements of malaria incidence, and
multiple analyses of the data.
We had some concerns  due to deviations from the intended
interventions. The participants were not blinded to the
intervention. However, the dropout rates were low with 79% of
participants in the control villages and 75% of the participants in
the intervention villages. No whole clusters were analysed in a
group diGerent from their allocation.
We judged there to be a low risk of bias arising from
the randomization process, along with adequate allocation
concealment. We judged there to be a low risk of bias due to low
levels of missing outcome data, with 14 out of the 263 children
recruited from the control villages and 10 of the 327 children from
the intervention villages lost to follow-up. We judged there to be
a low risk of bias in the measurement of the main outcome;  this
was standardized and the outcome assessors were blinded to the
intervention received.   See  Table 2  for a  summary of the RoB 2
judgments and justifications for malaria incidence.
For the outcome adverse events, we also judged it at an
overall  high risk of bias, due to the identification of participants
aVer randomization, and the selection of the reported result. We
noted an additional concern in the reporting of the significance of
the adverse event risk diGerence. The trial authors did not report
the P value for the adverse event risk diGerence of 1.21, 95% CI
0.04 to 2.38;  the values suggest a significant increase in adverse
events. However, as we judge the risk ratio to be the primary eGect
estimate, this did not aGect our overall risk of bias judgment. See
 Table 3 for a summary of the RoB 2 judgments and justifications for
adverse events.
E:ects of interventions
See: Summary of findings 1 Ivermectin versus control in humans
to reduce malaria transmission
Primary outcomes
Prevalence of malaria parasite infection
No included trials reported the eGect of mass administration of
ivermectin on the prevalence of malaria parasite infection.
Incidence of clinical malaria
Foy 2019  reported 648 malaria episodes in the intervention
group (327 children) and 647 episodes in the control group (263
children). We present the results using diGerent models of analysis
appropriate for cRCTs with small number of clusters.
The risk ratio  (RR) of malaria episodes between  the intervention
and  the control arms, when estimated using the Poisson mixed-
eGects model with small sample size correction, was 0.86  (95%
CI 0.62 to 1.17; P = 0.2607). The mean diGerence (MD) in the rate
of malaria episodes between arms when using the Poisson mixed
model with small-sample correction was -0.35 (95% CI -1.05 to
0.36; P = 0.2617). The mean diGerence in malaria episodes in the
cluster level analysis using weights accounting for variability in
cluster size   was  -0.34 (95% CI -0.90 to 0.22; P = 0.2829).  Figure
3 demonstrates the overlap of CIs of the malaria rates between each
cluster.
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Figure 3.   Distribution of the average number of malaria episodes per cluster.
 
Secondary outcomes
Mosquito mortality or survival
No included trials measured the eGect of mass administration of
ivermectin on mosquito mortality or survival.
Mosquito density
No included trials measured the eGect of mass administration of
ivermectin on mosquito density.
P falciparum sporozoite rates
The study authors did not share the sporozoites rate data  for
re-analysis but reported in the published report that it was not
noticeably diGerent between groups.
The reported weekly entomological inoculation rate was not
diGerent between the control and intervention arms (P = 0.956). The
study authors did not report the eGect size, nor did they share the
data for reanalysis.
P falciparum oocyst rates
No included trials measured the eGect of mass administration of
ivermectin on p falciparum oocyst rates.
Adverse eects
The trial authors did not provide us with safety data for re-analysis,
so we reported on the trial results presented in the published
report, which are unadjusted for the clustering eGect.
The reported risk of adverse events among all participants was
higher in the intervention group than in the control group. The
study reported 45 events (3%) from  1447 participants in the
intervention group, and 24 events (2%)  from 1265 in the control
group. The risk ratio (RR) was 1.63, 95% CI 1.01 to 2.67;  P =
0.060. Sixty-nine adverse events occurred in 65 (2%) participants
who reported one episode adverse event, and 4 (0.1%) participants
who reported a second event. Thirty-two  (49%) of these adverse
events were reported from the cohort of children.
The study authors deemed the adverse events that were classified
as possibly or probably related to the intervention as  adverse
reactions. There were five  (0.3%) adverse reactions in the
intervention group, and three (0.2%) in the control group. These
included vomiting, pruritus, oedema in the limbs, and tremors.
There were 20 (0.7%) deaths amongst all participants during the
trial period, which  were deemed unlikely or not related to the
intervention.
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D I S C U S S I O N
There is considerable interest in the use of ivermectin to
complement existing malaria control interventions. Individual-
based studies using laboratory-reared mosquitoes provide a proof-
of-concept on the eGicacy of ivermectin for  mosquito mortality
(Appendix 1). Modelling studies suggest that ivermectin can
reduce malaria transmission when used in combination with
other antimalarials (Slater 2020). However, currently, there is only
one published cluster-randomized controlled trial (cRCT) that has
assessed the role of ivermectin in reducing malaria transmission
(Foy 2019). This trial was registered as a pilot study and powered as
such.
Summary of main results
We included one cluster-randomized controlled trial (cRCT).
The study was conducted in Burkina Faso, with eight villages
randomized to two arms. Both trial arms received a single dose
of ivermectin 150 µg/kg to 200 µg/kg, together with a dose of
albendazole. Villages in the intervention arm received an additional
five doses of ivermectin, one every  three weeks. Children, aged
five years and younger, were enrolled in an active cohort, in which
they were repeatedly screened for malaria infection.
The primary outcome was the cumulative incidence of
uncomplicated malaria in the cohort of children, over the 18-
week study. The study did not demonstrate an eGect of ivermectin
on the cumulative incidence of uncomplicated malaria in the
cohort of children over the 18-week study (risk ratio  0.86, 95%
confidence interval (CI) 0.62 to 1.17;  P = 0.2607), although the study
was underpowered to detect the true eGect.
Overall completeness and applicability of evidence
While models of potential eGect have been used to inform possible
applications of the drug, the study included in this Cochrane
Review did not demonstrate an eGect of ivermectin on the
cumulative incidence of uncomplicated malaria. The benefits of the
intervention could be detected through future adequately powered
studies. There are a number of ongoing studies, which could
improve our understanding of the eGectiveness of this intervention
(see Characteristics of ongoing studies).
Quality of the evidence
We assessed the certainty of the evidence using the GRADE
approach, and presented it in the Summary of findings 1.
There was very low-certainty evidence about the eGicacy of
ivermectin in reducing the incidence of clinical malaria.  The eGect
estimate was based on a single trial with a high risk of bias.
Bias  arose  from the timing of identification and recruitment of
individual participants, and bias in the selection of the reported
result. This study was conducted as part of the scheduled yearly
mass treatment activities with ivermectin, which is relatively safe,
and has been given in Burkina Faso since the early 2000s. Therefore,
there may be potential biases due to participants' knowledge of the
drug and response to the intervention, compared to participants
who had not taken this drug before. Baseline imbalances in bed
net use and the number of children could represent diGerential
recruitment, although, this could also be compatible with chance
with cluster randomization. The multiple possible analyses of the
final result introduces bias. 
We also  downgraded due to imprecision, due to the  small
number of clusters and overlapping CIs. The eGect is indirect, as
the outcome was uncomplicated malaria, measured in children ≤ 5
years, most of whom would not have received the treatment due to
the ≥ 90 cm height requirement.
We judged the certainty of the evidence about the safety of
ivermectin to be very low because of imprecision, due to a low
number of events and a CI that included no eGect.
Potential biases in the review process
We re-analysed the primary data. We investigated potential bias
by conducting a sensitivity analysis using the three available
approaches for analysis when there is a small sample size in a
cluster-randomized trial.
We included only cluster-randomized trials, and this resulted in the
exclusion of several cohort or cross over trials that reported some of
the secondary outcomes. We have, however, included the RCT data
in Appendix 1.
Agreements and disagreements with other studies or
reviews
There has been no other systematic review conducted on
this topic. A narrative review by the  Ivermectin Roadmappers
2020 included Foy 2019 as the only study to demonstrate the eGect
of ivermectin MDA on malaria transmission.  In the review they
quoted a 20% reduction in malaria incidence in children < 5 years
old but acknowledge the debate over the statistical significance
of these findings, which was highlighted as inappropriate (Bradley
2019). For the mosquito lethal eGicacy data, they included trials
in which mosquitoes bloodfed on animal as well as human
blood donors (Ivermectin Roadmappers 2020). This highlighted the
variation in mosquito lethal eGects for ivermectin, depending on
the bloodmeal source.
We re-analysed the primary study data provided by the trial
authors. The methods that we used for the re-analysis to account
for clustering are, to our knowledge, all the available methods for
the analysis of cluster RCT's with a small sample size and all showed
consistent results.  The consistent lack of eGect in the reanalysis
diGers from the findings in the original publication. This lack of
eGect may be from a lack of power and not a lack of benefits from
the intervention.
We cannot make a conclusive inference on the eGect of ivermectin
on malaria transmission based on this single trial. However, it
highlights the importance of the process used in generating trial
results for reported outcomes.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Although ivermectin has been demonstrated to reduce the lifespan
of Anopheles mosquitoes (Appendix 1), we do not know if
community administration of ivermectin has an eGect on malaria
transmission.
The available evidence on the eGect of ivermectin on malaria
transmission comes from one published trial (Foy 2019).   The
intervention did not show an eGect in reducing the cumulative
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incidence of uncomplicated malaria. Therefore, we are uncertain
whether community administration of ivermectin reduces malaria
transmission.
Implications for research
The results of this trial, published in the Lancet, were contested
based on diGerences in the analytical protocol used in presenting
the primary outcome results (Bradley 2019; Foy 2019  (Foy
2019 Authors’ reply)). It is important that ongoing trials consider
and adopt a consistent protocol for analysis in cRCTs to improve
our confidence in the eGectiveness of ivermectin in malaria
transmission.
While children under five years of age are considered most
vulnerable to disease, transmission is more likely to be sustained
via the older population, who are typically asymptomatic carriers
(Bousema 2014; Lindblade 2013). Other trials reporting on the
incidence and prevalence of infection would be useful in addressing
the question of possible herd eGect in the community.
There are a number of trials in progress addressing
the question of whether community administration of ivermectin
reduces malaria transmission; the results will be included in
updates of this review when available (Rabinovich ongoing;
NCT04844905 (MATAMAL); NCT03074435 (REACT); NCT03576313
(MASSIV); NCT03967054 (RIMDAMAL II); PR150881). See details
in Characteristics of ongoing studies.
There is some uncertainty about what entomological
outcomes are critical for making public health decisions
and; recommendations,  and  how these should be measured.
Comparative data from ongoing trials could help address this.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Study design: cluster-randomized controlled trial (cRCT)
Study grouping: parallel groups
Participants Inclusion criteria: Individuals resident in study village, who consented to receive ivermectin and al-
bendazole in a mass drug administration (MDA) campaign
Exclusion criteria: children shorter than 90 cm, pregnant women, breastfeeding mothers with a baby
within 1 week of birth, a history of travel to an area endemic for Loa loa
Malaria transmission intensity at study site: hyper-endemic
Risk of contracting malaria: high
Demographics:
Age
Intervention: median 16 years (6 to 35 years)
Control: median 14 years (7 to 30 years)
Sex
Intervention: male 713 (49%), female 734 (51%)
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Control: 1094 (86%)
Coverage of MDA
Intervention: 75% in round 1; 73% in round 2, 3, and 4; 72 in round 5, and 70% in round 6
Control: 79% in the single round
 
Interventions Single dose ivermectin 150 μg/kg to 200 μg/kg with 400 mg albendazole given to both groups, followed
by five further doses of ivermectin at 3-week intervals to intervention group only
Outcomes Human outcomes
• Cumulative incidence of uncomplicated malaria episodes over the 18-week intervention period in the
cohort of children aged 5 years or younger (main outcome)
• Number and type of adverse events among enrolled participants, obtained by passive case detection
• Parasitaemia, multiplicity of infections (number of different P falciparum clones in each infection),
force of infection
• Serological reactivity to an anopheles salivary gland protein
• Prevalence of soil-transmitted helminthes in children aged 6 to 10 years
Entomological outcomes
• Human biting rate (number of mosquitoes that blood-fed or attempted to blood-feed per person per
week)
• Sporozoite rate (proportion of captured mosquitoes infected with sporozoites)
• Entomological inoculation rate (product of the human biting rate and the sporozoite rate)
• Proportion of parous mosquitoes
• Presence of Wuchereria bancrofti in captured mosquitoes
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Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Alout 2014 Wrong study design
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Study Reason for exclusion
Bockarie 1998 Wrong outcomes
Chaccour 2009 Not a cRCT
Chaccour 2010 Not a cRCT
Derua 2015 Not a cRCT
de Souza 2017 Wrong outcomes
Kobylinski 2011 Not a cRCT
Kobylinski 2017 Wrong study design
Kositz 2017 Wrong study design
Mekuriaw 2019 Not a cRCT
NCT02511353 Not a cRCT
Ouédraogo 2015 Not a cRCT
Pinilla 2018 Wrong study design
Smit 2018 Not a cRCT
RCT = randomized controlled trial; cRCT = cluster-randomized controlled trial
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Insecticide resistance management in Burkina Faso and Côte d'Ivoire (REACT)
Methods cRCT, parallel assignment
Participants Number: 18000; clusters: not stated
Interventions 1) insecticidal paints, 2) larvicides, 3) ivermectin for both human and domestic animals, and 4)
strengthened Information, Education and Communication (IEC) strategy to complement the uni-
versal coverage with LLINs
Outcomes Primary outcome measures:
1. Malaria incidence (time frame: continuous monitoring for 2 years)
Malaria cases reported in local health system
Secondary outcome measures:
1. Entomological inoculation rate (time frame: every 8 weeks for 2 years)
Number of infectious bites/person
         2. Malaria prevalence (Time frame: every 4 months for 2 years)
% of positive blood smears among the population between 6 months to 20 years
NCT03074435 (REACT) 
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Starting date 27 January 2010
Contact information Cédric Pennetier, PhD
Institut de Recherche pour le Développement
Notes Location: Burkina Faso and Côte d’Ivoire
Registration number: NCT03074435




Study name Mass drug administration of ivermectin and dihydroartemisinin-piperaquine as an additional inter-
vention for malaria elimination (MASSIV)
Methods Cluster-randomized, parallel-assignment trial
Participants Village residents aged 6 months and older, all genders
Interventions Intervention clusters: mass drug administration (MDA) with ivermectin (IVM) and dihy-
droartemisinin-piperaquine (DP) given to eligible participants plus the National Malaria Control
Program standard malaria control intervention
Control clusters: only standard malaria control interventions as implemented by the National
Malaria Control Program
Outcomes Primary outcomes:
• Prevalence of malaria infection determined by molecular methods
• Vector parous rate
Secondary outcomes:
• Malaria prevalence at the peak of the first transmission season
• Incidence of clinical (laboratory confirmed) malaria cases
• Serological markers of recent malaria
• Serological markers of recent Anopheles exposure
• Mosquito density
• Mosquito mortality
• Sporozoite rates in field-caught mosquitoes
Starting date August 2018
Contact information Umberto D'alessandro, MD, PhD +220-4495443-6 ext 4001; udalessandro@mrc.gm (PI)
Notes clinicaltrials.gov/ct2/show/NCT03576313
Location:  Gambia, Basse Villages
Registration number:  NCT03576313
Source of funding: MRC Unit, The Gambia
NCT03576313 (MASSIV) 
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Study name Repeat Ivermectin Mass Drug Administrations for MALaria control II (RIMDAMAL II)
Methods cRCT, parallel assignment
Participants Number: 4700; clusters: not stated
Description: eligible village population in southwestern Burkina Faso over two consecutive rainy
seasons eligible to receive MDA. Observe the effect for reducing the incidence of uncomplicated
malaria episodes in enrolled village children (≤ 10 years of age) assessed by active case surveillance
Interventions Mass administration of ivermectin or placebo will be given monthly over 4 months of each rainy
season to the eligible village population, each as 3-day course of 300 µg/kg/day
Outcomes Primary outcome measure:
• Malaria incidence (time frame: up to 8 months)
Secondary outcome measures:
• Adverse events (time frame: up to 25 months)
• Blood-fed mosquito mortality (time frame: up to 8 months)
• Entomological inoculation rate (time frame: approximately 8 months over 2 consecutive rainy sea-
sons (2019 to 2020))
• Human antibody responses to an Anopheles salivary gland peptide (time frame: up to 8 months)
• Plasmodium prevalence  (time frame: up to 8 months)
• Plasmodium parasitaemia (time frame: up to 8 months)
• Plasmodium multiplicity of infection (time frame: up to 8 months)
• Plasmodium molecular force of infection [time frame: up to 8 months)
Starting date 13 July 2019
Contact information Catherine Bens 970-491-5445; Cat.Bens@colostate.edu
Contact: Tammy Felton-Noyle 970-491-1655: Tammy.Felton-Noyle@colostate.edu
Notes Location: Burkina Faso
Registration number: NCT03967054 
Source of funding: National Institute of Health (NIH)




Study name Adjunctive Ivermectin Mass Drug Administration for Malaria Control (MATAMAL): a cluster ran-
domised placebo-controlled trial
Methods Phase three trial. Ivermectin will be compared to dihydroartemisinin-piperaquine (DP) treatment
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Outcomes Primary outcome: population-based Plasmodium falciparum prevalence (all ages)
Starting date 2019
Contact information Anna Last





Medical Research Council (MRC), UK
Wellcome Trust





Study name A novel vector control measure to combat the spread of Artemisinin resistance in the Greater
Mekong Subregion
Methods Two cRCTs, parallel assignment
Participants Number: not stated; clusters: not stated
Interventions (1) a two-arm trial to assess the impact of three ivermectin MDAs spaced 1 month apart in three vil-
lages compared to three control villages, and
(2) a three-arm trial to assess the impact of three dihydroartemisinin-piperaquine plus primaquine
with and without ivermectin MDAs spaced 1 month apart with each regimen distributed to two vil-
lages compared to two control villages
Outcomes Parameters of malaria transmission 
• Epidemiological (malaria prevalence, gametocytaemia, resistant parasite ratios, and haemoglo-
bin concentrations)
• Entomological (vector composition, density, sporozoite rate, resistant parasite ratios, and blood
meal composition)
Starting date 30 September 2016
Contact information Prachumsri, Jetsumon Mahidol University
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Study name BOHEMIA: Broad One Health Endectocide-based Malaria Intervention in Africa
Methods Two double-blinded cRCTs 
Participants Number: not stated; clusters: not stated
Description: Tanzania and Mozambique - during the malaria season; people and animals
Interventions Ivermectin
Outcomes Primary outcome: mosquito survival up to 28 days post blood-feeding
Secondary outcome: ivermectin plasma concentration ng/L
Starting date February 2019 to February 2023
Contact information Regina Rabinovich
Director of the Malaria Elimination Initiative; regina.rabinovich@isglobal.org






A D D I T I O N A L   T A B L E S
 
  Control N = 263 Intervention N = 327 Standardized
mean difference
(%)*
       
Individual-level covariates n (%) n (%)  
Male 120 (45.6)  159 (48.6)  6
Bednet use 229 (87.1)  314 (96.0)  32.6
Age 4 to 5 years  92 (35.0)  136 (41.6)  13.6
Height ≥ 90 cm 61 (23.2) 69 (21.1) 12.9
       
Age (median (Q1 to Q3)) , years 3 (1 to 4) 3 (1 to 4)  
       
Cluster-level covariate N = 4 N = 4  
Number of included children per village  43, 48, 58, 114 35, 66, 98, 128  
Table 1.   Baseline characteristics of the children, clusters, and households 
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Households N = 106 N = 127  
Household size (median (Q1 to Q3)) 2 (1 to 3) 2 (1 to 3)  
Table 1.   Baseline characteristics of the children, clusters, and households  (Continued)
*The standardized mean diGerence is a measure quantifying the imbalance between groups. A variable with a diGerence > 10% between
groups is considered unbalanced.
 
 
1a.1. Was the allocation sequence
random?
Y
1a.2. Was the allocation sequence
concealed until clusters were en-
rolled and assigned to interven-
tions?
Y
1a.3. Were there baseline imbal-
ances that suggest a problem with
the randomization process?
PN
Low risk Sealed envelopes containing the words 'treat-
ment' and 'control' were mixed in a contain-
er and randomly pulled from the container
by a community health worker representing
each village. There were large baseline imbal-
ances in bednet use; however, these differ-
ences could be due to chance. 
1b.1. Were all the individual partic-
ipants identified before randomiza-
tion of clusters?
N
1b.2. If N/PN/NI to 1b.1: is it likely
that selection of individual partic-
ipants was affected by knowledge
of the intervention?
NI
1b.3. Were there baseline imbal-
ances that suggest differential




High risk Enrolment of households took place after the
randomization of villages. Knowledge of mul-
tiple mass drug administrations (MDA) could
affect participant decision-making. Heads of
households discussed with the chiefs whether
to be involved in the study or not. See proto-
col pg 25. The baseline imbalance in bednet
use and the number of children could repre-
sent differential recruitment. However, this
could be compatible with chance with cluster
randomization.
 
2.1a. Were participants aware that
they were in a trial?
Y
2.1b. If Y/PY/NI to 2.1a: were partic-
ipants aware of their assigned in-
tervention during the trial?
Y
2.2. Were carers and trial personnel
aware of participants' assigned in-
tervention during the trial?
Y
2.3. If Y/PY/NI to 2.1 or 2.2: were
there deviations from the intended
intervention that arose because of
the trial context?
NI
2.4. If Y/PY to 2.3: were these de-
viations from intended interven-
tion unbalanced between groups
NA
Some concerns The study was blinded only to the outcome-
 assessor, who was allowed access only to the
coded group and participant data when doing
the initial analyses. The participants or carers
were not blinded to the intervention. Devia-
tions from the intended intervention were not
reported.
Table 2.   RoB 2 for cluster-randomized trials summary of judgments: malaria Incidence  
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and likely to have affected the out-
come?
2.5a. Were any clusters or partici-
pants analysed in a group different
from the one to which they were as-
signed?
NA
2.6. Was an appropriate analysis
used to estimate the effect of as-
signment to intervention?
NI
2.7. If N/PN/NI to 2.6: was there po-
tential for a substantial impact (on
the result) of the failure to analyse
participants in the group to which
they were randomized?
N
3.1a. Were outcome data available
for all, or nearly all, clusters ran-
domized?
Y
3.1b. Were outcome data available
for all, or nearly all, participants
within clusters?
Y
3.2. If N/PN/NI to 3.1: are the pro-
portions of missing outcome data
and reasons for missing outcome
data similar across intervention
groups?
NA
3.3. If N/PN/NI to 3.1: is there evi-
dence that results were robust to
the presence of missing outcome
data?
NA
Some concerns Data were available for all clusters random-
ized. 14 children were lost to follow-up-
 from the control group, and 10 from the in-
tervention group. Data were available in all
clusters. 
“Participation in mass drug administrations
in the intervention group started at 1080
(75%) of 1447 enrolled village residents and
dropped slightly over subsequent administra-
tions: 1056 (73%) in the second, 1051 (73%) in
the third, 1060 (73%) in the fourth, 1037 (72%)
in the fiVh, and 1020 (70%) in the sixth admin-
istration. In the control group, 999 (79%) of
1265 people participated in the mass drug ad-
ministration.” There was a fall in coverage in
the intervention arm, however, as the control
had no placebo, it is difficult to say if the devi-
ations arose because of the trial context. They
did not state whether they compared a per-
protocol analysis or ITT analysis.
4.1. Was the method of measuring
the outcome inappropriate?
N
4.2. Could measurement or as-




4.3a. If N/PN/NI to 4.1 and 4.2: were
outcome assessors aware that a tri-
al was taking place?
Y
4.3b. If Y/PY/NI to 4.3a: were out-
come assessors aware of the inter-





The method of measuring malaria incidence
is acceptable in public health malaria trials.
  The outcome (cumulative incidence of un-
complicated malaria episodes in children ≤ 5
years of age) was assessed by active case sur-
veillance in study villages 2X/week – a malar-
ia episode was defined as ≥ 38.0 °C fever or
a history of fever in the last 24 hours + posi-
tive rapid diagnostic test for Plasmodium fal-
ciparum. There was an objective protocol for
measurement. The study was blinded only
to the outcome assessor, who was allowed
access only to the coded group and partici-
pant data when doing the initial analyses. The
outcome assessor was defined as the asses-
sor conducting the analysis. It was unlikely
that the awareness of the outcome assessor-
 would have influenced the outcome mea-
surement. 
 
Table 2.   RoB 2 for cluster-randomized trials summary of judgments: malaria Incidence   (Continued)
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5.1. Were the data that produced
this result analysed in accordance
with a prespecified analysis plan
that was finalized before unblind-
ed outcome data were available for
analysis?
NI
Is the numerical result being as-
sessed likely to have been selected,
on the basis of the results, from...
 
5.2. ...multiple eligible outcome
measurements (e.g. scales, defini-
tions, time points) within the out-
come domain?
Y
5.3 ...multiple eligible analyses of
the data?
Y
High risk There was a prespecified analysis plan, how-
ever, it did not detail the method of cluster
adjustment used. 
They used clinical malaria -definition uncom-
plicated only.
Malaria episode was defined by a tempera-
ture of 38.0°C or higher (0.5°C was added to
each thermometer recording to account for
axillary readings) or history of fever in the last
24 h, and a positive rapid diagnostic test (SD
Bioline Malaria Ag P.f/Pan; Alere, Inc) for Plas-
modium. Rapid diagnostic tests were consid-
ered positive if any test line appeared (histi-
dine-rich protein II antigen of P falciparum, or
common lactate dehydrogenase of Plasmodi-
um sp, or both), and incidence data were not
modified in response to these results.
 
As demonstrated in the review, the method of
adjustment can influence the results.
 
Table 2.   RoB 2 for cluster-randomized trials summary of judgments: malaria Incidence   (Continued)
Y: Yes; N: No, PY: Probably Yes, PN: Probably No, NI: No Information
 
 
1a.1. Was the allocation sequence ran-
dom?
Y
1a.2. Was the allocation sequence
concealed until clusters were enrolled
and assigned to interventions?
Y
1a.3. Were there baseline imbalances
that suggest a problem with the ran-
domization process?
PN
Low risk Sealed envelopes containing the words
'treatment' and 'control' were mixed in a
container and randomly pulled from the
container by a community health work-
er representing each village. There were
large baseline imbalances in bednet use;
however, these differences could be due to
chance. 
1b.1. Were all the individual partici-
pants identified before randomization
of clusters?
N
1b.2. If N/PN/NI to 1b.1: is it likely that
selection of individual participants
was affected by knowledge of the in-
tervention?
PY
1b.3. Were there baseline imbalances
that suggest differential identifica-
tion or recruitment of individual par-
ticipants between arms?
N
High risk Enrolment of households took place af-
ter the randomization of villages. Knowl-
edge of multiple mass drug administra-
tions (MDA) could affect participant de-
cision-making. Heads of households dis-
cussed with the chiefs whether to be in-
volved in the study or not. See protocol pg
25. The baseline imbalance in bednet use,
and the number of children could repre-
sent differential recruitment. However, this
could be compatible with chance with clus-
ter randomization.
 
Table 3.   RoB 2 for cluster-randomized trials summary of judgments: adverse events 
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2.1a. Were participants aware that
they were in a trial?
Y
2.1b. If Y/PY/NI to 2.1a: were partici-
pants aware of their assigned inter-
vention during the trial?
Y
2.2. Were carers and trial personnel
aware of participants' assigned inter-
vention during the trial?
Y
2.3. If Y/PY/NI to 2.1 or 2.2: were there
deviations from the intended inter-
vention that arose because of the trial
context?
NI
2.4. If Y/PY to 2.3: were these devia-
tions from intended intervention un-
balanced between groups and likely
to have affected the outcome?
NA
2.5a. Were any clusters or partici-
pants analysed in a group different
from the one to which they were as-
signed?
NA
2.6. Was an appropriate analysis used
to estimate the effect of assignment
to intervention?
NI
2.7. If N/PN/NI to 2.6: was there po-
tential for a substantial impact (on
the result) of the failure to analyse
participants in the group to which
they were randomized?
N
Some concerns The study was blinded only to the outcome
assessor, who was allowed access only
to the coded group and participant data
when doing the initial analyses. The partic-
ipants or carers were not blinded to the in-
tervention. Deviations from the intended
intervention were not reported. Although
14 children were lost to follow-up from the
control group and 10 from the intervention
groups. 
“Participation in mass drug administra-
tions in the intervention groups started
at 1080 (75%) of 1447 enrolled village res-
idents and dropped slightly over subse-
quent administrations: 1056 (73%) in the
second, 1051 (73%) in the third, 1060 (73%)
in the fourth, 1037 (72%) in the fiVh, and
1020 (70%) in the sixth administration. In
the control group, 999 (79%) of 1265 peo-
ple participated in the mass drug adminis-
tration.” There was a fall in coverage in the
intervention arm; however, as the control
had no placebo, it is difficult to say if the
deviations arose because of the trial con-
text. They did not state whether they com-
pared a per-protocol analysis or ITT analy-
sis. It is very unlikely that entire clusters
were analysed in the wrong group.
3.1a. Were outcome data available for
all, or nearly all, clusters randomized?
Y
3.1b. Were outcome data available for
all, or nearly all, participants within
clusters?
Y
3.2. If N/PN/NI to 3.1: are the propor-
tions of missing outcome data and
reasons for missing outcome data
similar across intervention groups?
NA
3.3. If N/PN/NI to 3.1: is there evi-
dence that results were robust to the
presence of missing outcome data?
NA
Some concerns Data were available for all clusters ran-
domized. 14 children were lost to follow-up
from the control group and 10  from the in-
tervention group. Data were available in all
clusters. 
 
4.1. Was the method of measuring the
outcome inappropriate?
N
4.2. Could measurement or ascertain-






The method of measuring malaria inci-
dence is acceptable in public health malar-
ia trials. There was an objective protocol
for measurement. The study was blinded
only to the outcome assessor, who was
allowed access only to the coded group
and participant data when doing the initial
Table 3.   RoB 2 for cluster-randomized trials summary of judgments: adverse events  (Continued)
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4.3a. If N/PN/NI to 4.1 and 4.2: were
outcome assessors aware that a trial
was taking place?
Y
4.3b. If Y/PY/NI to 4.3a: were outcome
assessors aware of the intervention
received by study participants?
Y
4.4. If Y/PY/NI to 4.3b: could assess-
ment of the outcome have been influ-
enced by knowledge of intervention
received?
PN
4.5. If Y/PY/NI to 4.4: is it likely that as-
sessment of the outcome was influ-
enced by knowledge of intervention
received?
NA
analyses.  The outcome assessor was de-
fined as the assessor conducting the analy-
sis. It was unlikely that the awareness of
the outcome assessor would have influ-
enced the outcome measurement. 
Adverse events were reported to the study
team. Adverse events were objective mea-
sures.  They included all adverse events,
whether related directly to the interven-
tion or not. They were then analysed as be-





5.1. Were the data that produced this
result analysed in accordance with a
prespecified analysis plan that was fi-
nalized before unblinded outcome da-
ta were available for analysis?
PY
Is the numerical result being assessed
likely to have been selected, on the
basis of the results, from...
 
5.2.  ...multiple eligible outcome mea-
surements (e.g. scales, definitions,
time points) within the outcome do-
main?
Y
5.3. ...multiple eligible analyses of the
data?
Y
High risk Statistical Analysis Plan and protocol avail-
able. Participants had repeated adverse
events with multiple categorizations of
severity and relation to the intervention.
The data were not cluster adjusted. The
analysis was by events rather than by the
individuals. No adjustment of the result.
 
Table 3.   RoB 2 for cluster-randomized trials summary of judgments: adverse events  (Continued)
Y: yes; N: no, PY: probably yes, PN: probably no, NI: no information
 
 
A P P E N D I C E S
Appendix 1. The e:ect of ivermectin treatment in humans on mosquito mortality: a systematic review of
randomized controlled trials
Background
Our review question was whether ivermectin could reduce transmission in the community, but first, we wanted to establish its direct eGect
on mosquitoes. We sought the answer by summarising the data from randomized controlled trials (RCTs) of mosquito-feeding experiments
in human participants treated with ivermectin.
Methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 14 January 2021, Issue 1 of 12) in the Cochrane Library (searched
14 January 2021), MEDLINE Pubmed (1946 to 14 January 2021), Embase Ovid, (1974 to 14 January 2021), and Web of Science (searched 14
January 2021), using the search terms: ivermectin or avermectin or abamectin AND Anopheles or mosquitocid. We selected  randomized
trials that gave ivermectin at standard doses used for current mass drug administration (MDA) regimes to malaria-infected or healthy
individuals. Our inclusion criteria were RCTs of healthy or malaria-infected people who had taken oral ivermectin, then given blood for
membrane feeding or direct arm feeding on Anopheles species mosquitoes.
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Two authors  (RT and JO) independently reviewed the search results and agreed on selected articles for full-text review. To maintain
consistency with the main review aims, we applied the same methods for data extraction and analysis as published in the main review
protocol (de Souza 2018). The primary outcome for this review was mosquito mortality. Secondary outcomes included  cumulative
mortality rates, oocyte rates, and adverse event rates in humans.
Results
We identified 195 articles, of which we included five (Chaccour 2010; Derua 2015; Mekuriaw 2019; Ouédraogo 2015; Smit 2018); see Table
1 in this appendix.
Description of studies
All included studies reported mosquito mortality as their primary outcome. All studies used laboratory-reared mosquitoes.
One trial recruited people with  symptomatic  Plasmodium falciparum  infections  (Smit 2018), one trial enrolled people with
asymptomatic P falciparum  infections (Ouédraogo 2015), and three trials recruited uninfected volunteers (Chaccour 2010; Derua 2015;
Mekuriaw 2019;  Table 1 in this appendix). Three of the studies used direct arm-feeding for mosquitoes (Chaccour 2010; Derua 2015;
Mekuriaw 2019), while two studies used feeding membranes (Ouédraogo 2015; Smit 2018). Four studies used An gambiae (Chaccour 2010;
Derua 2015; Ouédraogo 2015; Smit 2018), while one study each used An funestus (Ouédraogo 2015), and An arabiensis (Mekuriaw 2019)
for the feeding experiments. 
Mosquito mortality was reported diGerently in each study. In three studies, it was reported as a hazard ratio (Chaccour 2010; Ouédraogo
2015; Smit 2018 ). Three studies reported the mean cumulative daily mortality (Chaccour 2010 ; Derua 2015; Smit 2018 ), while Mekuriaw
2019  presented the mean daily mortality.  Ouédraogo 2015  presented mosquito mortality data as geometric mean cumulative daily
mortality.
Risk of bias
We assessed the risk of bias using the RoB 2 tool (Sterne 2019; see Table 2 in this appendix). We measured bias across five domains: the
randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of
the reported result. Apart from Smit 2018, prespecified statistical analysis plans were not available. As there were multiple outcome
measurements and methods of statistical analyses used in the other four studies, we judged them as having a high risk of bias.
Eect on mortality
Overall, all studies showed large eGects of ivermectin on mosquito mortality for variable periods, depending on the total dose of ivermectin
given to human participants, the mosquito species, and day of blood meal post-treatment.
In the Smit 2018 study, the largest eGect on mortality was seen when the blood meal was given two days aVer ivermectin ingestion of 600
μg/kg/day for three days (hazard ratio (HR) 12.58, 95% confidence interval (CI) 9.98 to 15.36), or 300 μg/kg/day for three days (HR 9.59, 95%
CI 7.77 to 11.82; Table 3). The eGect on mosquito mortality waned when the time period between ivermectin ingestion and feeds increased.
The eGect on day 28 was much lower; aVer 600 μg/kg/day for three days (HR 1.65, 95% CI 1.18 to 2.31), and 300 μg/kg/day for three days
(HR 1.33, 95% CI 0.96 to 1.84; see Table 3 in this appendix).
Chaccour 2010 used a diGerent dose of ivermectin and measured mortality at diGerent time points, but found similar trends in mosquito
mortality rates (Table 4). The largest eGect was seen when the blood meal was given one day following a single dose of ivermectin 200
μg/kg/day (HR 2.22, 95% CI 1.83 to 2.7), which diminished by day 14 aVer a single dose of ivermectin 200 μg/kg/day (HR 1.07, 95% CI 0.87
to 1.31; Table 4).
Ouédraogo 2015 found a larger eGect on An funestus mosquitoes following a single dose of ivermectin 200 μg/kg/day (HR 2.98, 95% CI
1.62 to 5.48), and ivermectin 200 μg/kg/day for three consecutive days (HR 9.07, 95% CI 5.06 to 16.25; Table 5), compared to the eGect
on An gambiae mosquitoes following a single dose of ivermectin 200 μg/kg/day (HR 1.37, 95% CI 1.14 to 1.65), and ivermectin 200 μg/kg/
day for three days (HR 4.07, 95% CI 3.41 to 4.87; Table 6). The eGect diminished by day seven in the An gambiae mosquitoes following a
single dose of ivermectin 200 μg/kg/day (HR 0.93, 95% CI 0.79 to 1.11) and three days of ivermectin 200 μg/kg/day (HR 1.3, 95% CI 1.1 to
1.53; Table 5).
The data on cumulative mortality demonstrated a consistent and dose-dependent eGect on mosquito mortality in the ivermectin arm
(Tables 7 to 12). This eGect on mortality decreased as the number of days between oral ivermectin the blood meal increased. Higher doses
of ivermectin prolonged the eGect, indicating an increased time of lethal concentration of ivermectin in the blood. 
Conclusion
Ivermectin has a large eGect on mosquito mortality. The eGect is larger when mosquitoes feed soon aVer ivermectin administration, and
when the dose of ivermectin is higher; the eGect varies with mosquito species.
Ivermectin treatment in humans for reducing malaria transmission (Review)















































































































Table 1: Randomized controlled trials of the eect of oral ivermectin in humans on blood-fed mosquitoes























Untested endemic setting Ethiopia Arm feeding An arabiensis 175a 1 No drug Nil 1, 4, 7, 10, 13
Derua
2015





Untested non-endemic setting United
Kingdom
Arm feeding An gambiae 200 1 No drug Nil 1, 14






























































































Cochrane Database of Systematic Reviews


















Ouédraogo 2015 + + + + ­- -
Derua 2015 + + + + - -
Smit 2018 + + + + + +
Chaccour 2010 ? + + + - -
Mekuriaw 2019 + + + + - -
Key: + Low risk; ? Some concerns; + High risk
 
 
Trials reporting Cox’s proportional hazard ratio for mosquito mortality (Tables 3 to 6)
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2 300 3 30 9.59 (7.77 to 11.82) 5039 1154 229  917 (868 to 954)
2 600 3 30 12.58 (9.98 to 15.36) 5039 1154 229  962 (925 to 982)
7 300 3 35 4.21 (3.06 to 5.79) 4277 1052 246  695 (579 to 805)
7 600 3 35 6.32 (4.61 to 8.67) 4277 1052 246  832 (728 to 914)
10 300 3 38 2.71 (1.85 to 3.97) 3726 1023 275  581 (448 to 720)
10 600 3 38 3.66 (2.51 to 5.33) 3726 1023 275  691 (553 to 819)
14 300 3 42 2.25 (1.6 to 3.16) 4043 1010 250  476 (369 to 597)
14 600 3 24 3.74 (2.67 to 5.26) 4043 1010 250  659 (536 to 780)
28 300 3 56 1.33 (0.96 to 1.84) 3991 1358 248  315 (239 to 408)
28 600 3 56 1.65 (1.18 to 2.31) 3991 1358 248  375 (285 to 482)




































































































































































































per 1000 (95% CI)
1 200 1 13 2.22 (1.83 to 2.7) 250 179 716  939 (900 to 967)
14 200 1 26 1.07 (0.87 to 1.31) N/A N/A N/A N/A





































































































































































































1 200 1 10  7.12 (4.45 to 11.39) N/A N/A N/A N/A
3 200 1 10 2.98 (1.62 to 5.48) N/A N/A N/A N/A
3 200 3 10 9.07 (5.06 to 16.25) N/A N/A N/A N/A





































































































































































































1 200 1 11 3.86 (3.29 to 4.52) N/A N/A N/A N/A
3 200 1 13 1.37 (1.14 to 1.65) N/A N/A N/A N/A
3 200 3 13 4.07 (3.41 to 4.87) N/A N/A N/A N/A
7 200 1 17 0.93 (0.79 to 1.11) N/A N/A N/A N/A
7 200 3 17 1.3 (1.1 to 1.53) N/A N/A N/A N/A
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Studies reporting mosquito cumulative mosquito mortality per day (Tables 7 to 9)
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Table 7: E:ect of ivermectin on mortality in An gambiae (Chaccour 2010)












mectin Events Total Events Total Percentage mortality Percentage mor-
tality
3 194 267 78 250 72.7 31.2
4 223 267 94 250 83.5 37.6
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Table 8: E:ect of ivermectin on mortality in An gambiae mosquitoes (Smit 2018)















mectin Events Total Events Total Percentage mortality Percentage
mortality
6 4353 5043 670 5039 86.3 13.3
10 4851 5043 1154 5039 96.2 22.9
300
 
14 4985 5043 2778 5039 98.9 55.1
6 4183 4666 670 5039 89.7 13.3










14 4560 4666 2778 5039 97.7 55.1
11 2146 4239 586 4277 50.6 13.7





19 3941 4239 2336 4277 93 54.6
11 3342 4763 586 4277 70.2 13.7












19 4610 4763 2336 4277 96.8 54.6
18 1037 3992 641 4043 26 15.9






































































































































































































18 1645 4234 641 4043 38.9 15.9







26 3394 4234 2225 4043 80.2 55
300 40 2268 4007 2952 3991 56.6 7428
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1 150 to 200 1 2 67.5 750 25.5 750 9 3.4
1 150 to 200 1 3 369 750 42 750 49.2 5.6
1 150 to 200 1 4 499.5 750 54 750 66.6 7.2
1 150 to 200 1 5 594 750 64.5 750 79.2 8.6
1 150 to 200 1 10 724.5 750 333 750 96.6 44.4
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Studies that report mean daily mortality in mosquitoes
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Table 10: The e:ect of ivermectin on An arabiensis mosquitoes (Mekuriaw 2019)












mectin Events Total Events Total Percentage mortality Percentage
mortality
1 6 55.2 304 7.4 160 18.2 4.6
3 8 44.76 324 6.92 16 13.8 4.1
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Studies that report geometric mean cumulative mortality by day 10 (Table 11 and Table 12)
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Table 11: The e:ect of ivermectin in An gambiae mosquitoes (Ouedrogo 2015)                      













mectin Events Total Events Total Percentage mortality Percentage mor-
tality
1 1 11 N/A N/A N/A N/A 59.1 21.1
4 1 14 N/A N/A N/A N/A 31.1 21.2
4 3 14 N/A N/A N/A N/A 66.2 21.2
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Table 12: The e:ect of ivermectin on An funestus mosquitoes (Ouedraogo 2015)
















1 200 1 11 N/A N/A N/A N/A 40 5
4 200 1 14 N/A N/A N/A N/A 10.9 5
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Appendix 2. Detailed search strategies
Database: Cochrane Central Register of Controlled Trials
#1 malaria*:ti,ab,kw or plasmodium:ti,ab,kw (Word variations have been searched)
#2 anopheles:ti,ab,kw or mosquito*:ti,ab,kw (Word variations have been searched)
#3 #1 or #2
#4 MeSH descriptor: [Ivermectin] explode all trees
#5 ivermectin:ti,ab,kw (Word variations have been searched)
#6 "abamectin":ti,ab,kw (Word variations have been searched)
#7 "avermectin":ti,ab,kw (Word variations have been searched)
#8 #4 or #5 or #6 or #7




#1 Search malaria Field: Title/Abstract
#2 Search "Malaria"[Mesh]
#3 Search "Plasmodium"[Mesh]
#4 Search plasmodium Field: Title/Abstract
#5 Search anopheles Field: Title/Abstract
#6 Search "Anopheles"[Mesh]
#7 Search mosquito* Field: Title/Abstract
#8 Search ((((((#7) OR #6) OR #5) OR #4) OR #3) OR #2) OR #1
#9 Search "abamectin" [Supplementary Concept]
#10 Search ivermectin Field: Title/Abstract
#11 Search "Ivermectin"[Mesh]
#12 Search avermectin Field: Title/Abstract
#13 Search abamectin Field: Title/Abstract
#14 Search ((((#13) OR #12) OR #11) OR #10) OR #9
#15 Search (#14) AND #8
#16 Search "Drug Therapy"[Mesh]
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#17 Search randomly Field: Title/Abstract
#18 Search controlled clinical trial Field: Title/Abstract
#19 Search placebo or trial Field: Title/Abstract
#20 Search randomized controlled trial Field: Title/Abstract
#21 Search "Randomized Controlled Trial" [Publication Type] OR "Controlled Clinical Trial" [Publica-
tion Type]
#22 Search ((((#21) OR #20) OR #19) OR #18) OR #17 OR #16
#23 Search (#22) AND #15
  (Continued)
 
Database: Embase (1947 to present, updated daily)
--------------------------------------------------------------------------------
1) malaria/ or malaria.mp.
2) Plasmodium/ or plasmodium.mp.
3) Anopheles/ or anopheles.mp.
4) mosquito*.mp. or mosquito/
5) 1 or 2 or 3 or 4
6) ivermectin/ or ivermectin.mp.
7) abamectin.mp. or abamectin/
8) avermectin.mp. or avermectin/
9) 6 or 7 or 8
10) 5 and 9
11) controlled clinical trial.mp. or Controlled Clinical Trial/
12) randomized controlled trial.mp. or Randomized Controlled Trial/
13) (randomized or placebo or double-blind* or single-blind*).mp.
14) randomization/
15) crossover procedure/
16) 11 or 12 or 13 or 14 or 15
17) 10 and 16
Database: LILACS
Search on: malaria or mosquito [Words] and ivermectin or abamectin [Words]
Web of Science
 
# 3 #2 AND #1
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Indexes=SCI-EXPANDED, Timespan=All years
# 2 TOPIC: (randomized trial or clinical trial) OR TOPIC: (double-blind* or single-blind* or placebo)
Indexes=SCI-EXPANDED, Timespan=All years
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Irene Larbi stepped down from the review team. Rebecca Thomas, John Bradley, and Clemence Leyrat joined the review team.
We prioritized the review outcomes, focusing on outcomes in humans.
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Prior to the screening process, we amended the protocol inclusion criteria to exclude studies using toxic sugar baits.
We were provided with the primary data by the study authors. We re-analysed the primary data using a Poisson mixed model with small
sample size correction (Kenwood-Rodger), as well as cluster-level analysis using a linear weighted model in order to minimise the type 1
error rate (Kahan 2016).
We assessed risk of bias using the revised Cochrane risk of bias tool for randomised trials (RoB 2.0), with additional considerations for
cRCTs,  as this was deemed best able to summarise the biases particular to cluster trials (Eldridge 2021).
We included a  nested systematic review of the randomized controlled trials examining the eGect of ivermectin given to individually
randomized people on mosquito mortality in the appendix.
As we only included one study  in the review, we were unable to  assess heterogeneity,  reporting biases, synthesize data, or conduct
sensitivity or subgroup analyses.
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